The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: Protocol for a systematic review and meta-analysis

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Druyts, Eric ^a   Eapen, Shawn ^a   Wu, Ping ^a   Thorlund, Kristian ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Antipsychotics; Children; Meta analysis; Pediatric; Prolactin; Schizophrenia; Systematic review

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

ARTICLE; AUTISM; DRUG SAFETY; GALACTORRHEA; GYNECOMASTIA; HUMAN; MENSTRUATION DISORDER; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDITY; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CHILD; FEMALE; MALE; METHODOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMANS; MALE; MENSTRUATION DISTURBANCES; PROLACTIN; RESEARCH DESIGN; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84928031307     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-116     Document Type: Article

References (39)

1. Vitiello B, Correll C, Van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009, 19:629-635. 10.1016/j.euroneuro.2009.04.008, 19467582.
2. Correll C. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008, 47:9-20. 10.1097/chi.0b013e31815b5cb1, 18174821.
3. Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012, 57(1):52-58.
4. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolescent Psychopharmacol 2011, 21(6):537-543.
5. Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 2011, 7(5):591-608. 10.1517/17425255.2011.562198, 21401439.
6. Elias M. New antipsychotic drugs carry risks for children. USA Today 2006, [http://usatoday30.usatoday.com/news/health/2006-05-01-atypical-drugs_x.htm].
7. Harris G. Use of antipsychotics in children is criticized. New York Times 2008, [http://www.nytimes.com/2008/11/19/health/policy/19fda.html?_r=0].
8. Goffin V, Shiverick K, Kelly P, Martial J. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev 1996, 17:385-410.
9. Nicoll C, Mayer G, Russell S. Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev 1986, 7:169-203. 10.1210/edrv-7-2-169, 3013605.
10. Forsyth I, Wallis M. Growth hormone and prolactin-molecular and functional evolution. J Mammary Gland Biol Neoplasia 2002, 7:291-312. 10.1023/A:1022804817104, 12751893.
11. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen R. Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004, 65:1491-1498. 10.4088/JCP.v65n1108, 15554761.
12. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(Suppl 1):53-67.
13. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007, 61(4):545-550. 10.1016/j.biopsych.2006.02.032, 16730335.
14. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003, 64(11):1362-1369. 10.4088/JCP.v64n1113, 14658952.
15. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 2003, 28(Suppl 2):109-123.
16. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999, 19(1):57-61. 10.1097/00004714-199902000-00011, 9934944.
17. Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002, 181:271-275. 10.1192/bjp.181.4.271, 12356650.
18. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001, 53(1):119-133.
19. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatr 2000, 157:514-520. 10.1176/appi.ajp.157.4.514, 10739409.
20. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011, 34(8):651-668. 10.2165/11592020-000000000-00000, 21751826.
21. Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T,. CAMESA guideline group Recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011, 20:234-241. 3143701, 21804854, CAMESA guideline group.
22. Pfeiffer D, Brûlé-Brown D. Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents. Canadian Adverse Reaction Newslett 2012, 22(1):1-2.
23. Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, Perkinds D, Kreyenbuhl J,. American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(2 Suppl):1-56. American Psychiatric Association.
24. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, Van Os J, Carpenter W. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013, 150(1):3-10. 10.1016/j.schres.2013.05.028, 23800613.
25. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2009, London: The Cochrane Collaboration.
26. Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, You JJ, Bassler D, Lamontagne F, Vera C, Alshurafa M, Katsios CM, Heels-Ansdell D, Zhou Q, Mills E, Guyatt GH. The reliability and validity of estimating unclearly reported blinding status in randomized clinical trials. J Clin Epidemiol 2012, 65:262-267. 10.1016/j.jclinepi.2011.04.015, 22200346.
27. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Group GW. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336(7650):924-926. 10.1136/bmj.39489.470347.AD, 2335261, 18436948.
28. Salanti G, Del Giovane C, Chairmani A, Cadwell D, Higgins J. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014, 9(7):e99682. 10.1371/journal.pone.0099682, 4084629, 24992266.
29. Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 2013, 7(5):e2195. doi: 10.1371/journal.pntd.0002195, 10.1371/journal.pntd.0002195, 3642227, 23658850.
30. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23(20):3105-3124. 10.1002/sim.1875, 15449338.
31. Mills E, Ioannidis J, Thorlund K, Schunemann H, Puhan M, Guyatt G. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012, 308:1246-1253. 10.1001/2012.jama.11228, 23011714.
32. Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol 2012, 12:111. 10.1186/1471-2288-12-111, 3564789, 22846171.
33. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013, 11:159. doi: 10.1186/1741-7015-11-159, 10.1186/1741-7015-11-159, 3707819, 23826681.
34. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011, 64(2):163-171. 10.1016/j.jclinepi.2010.03.016, 20688472.
35. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol 2012, 32(3):309-316. 10.1097/JCP.0b013e3182549259, 22544019.
36. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011, 21(8):621-645. 10.1016/j.euroneuro.2010.07.002, 20702068.
37. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012, 129(3):e771-e784. 10.1542/peds.2011-2158, 22351885.
38. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014, 28(5):421-453. 4022988, 24677189.
39. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolescent Psychopharmacol 2009, 19(4):403-414.